X4 Pharma: NDA accepted for mavorixafor in WHIM with PDUFA April 30, 2024; Q3 net loss $2.3M

X4 Pharmaceuticals, Inc

2023-Q3 EPS reported -$0.48

FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome with Priority Review; PDUFA target April 30, 2024; eligible for Priority Review Voucher if approved.
Ongoing Phase 2 chronic neutropenia data to be presented at ASH Dec 9-12, 2023; Phase 3 trial initiation expected 1H 2024.
Q3 2023 cash, equivalents, and marketable securities totaled $142.7M; net loss of $2.3M (incl. $25.2M non-cash gain vs. $21.6M net loss in Q3 2022).
Completed $115M debt facility with Hercules Capital; initial draw of $22.5M in August 2023.
Appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer in August 2023; added R. Keith Woods to Board of Directors in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2023 results: net income Net Loss: X4 reported a net loss of $2.3 million for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Net income: Net Loss: X4 reported a net loss of $2.3 million for the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-038053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.